Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2008

View Archived Issues

Novel anticoagulants disclosed in recent Novo Nordisk patent

New treatment options for AD and other cognition disorders described in recent Roche patent

New clinical data on pazopanib presented

MDRNA selects MDR-04227 as lead candidate in hypercholesterolemia program

Recent Plexxikon and Janssen patents impart novel antiobesity drugs

Kamada presents positive phase II data for inhaled AAT in cystic fibrosis

Biodel to meet with FDA by end of January 2009 to discuss NDA for diabetes drug VIAject

Natural extract derivative found as novel PDE5A1 inhibitor with better selectivity than sildenafil

BioWa and CSL sign license agreement for Potelligent technology in ADCC-enhanced antibodies

AZD-1152-HQPA enhances oxaliplatin effects in colorectal tumor model

Pfizer presents data on asthma candidate Compound X

HE-3235 inhibits tumor growth in castration-resistant prostate cancer model

Ablynx presents update on development of Nanobodies antibody-derived therapeutic proteins

Glenmark initiates phase II study of PDE4 inhibitor oglemilast in asthma

OncoGenex achieves regulatory milestone for lead product candidate, OGX-011

Ostarine meets primary endpoint in phase II cancer cachexia trial

Avontec reports results of phase IIa AVT-02 trial in psoriasis

FDA agrees with Neurobiological to consolidate Viprinex phase III trials

R&D highlights from the UBS Global Life Sciences Conference in New York: Vical Incorporated

Revotar presents phase I data for bimosiamose 5% cream in psoriasis

Sweden grants approval to Cyto Pulse to initiate phase I/II trial of a xenogenic DNA vaccine

Genmab reaches milestone following initiation of treatment in phase I study of ofatumumab

FDA grants marketing approval to Boston Scientific's Taxus Liberte paclitaxel-eluting stent

Migenix presents update on development of Omigard for catheter-related infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...